InMode Ltd. (NASDAQ:INMD) Given Consensus Recommendation of “Hold” by Analysts

Shares of InMode Ltd. (NASDAQ:INMD) have earned an average recommendation of “Hold” from the eight brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $17.25.

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of InMode in a research note on Thursday, January 22nd. Robert W. Baird set a $17.00 price target on shares of InMode in a research note on Wednesday, February 11th. Finally, BTIG Research restated a “neutral” rating on shares of InMode in a research note on Monday, January 26th.

Institutional Trading of InMode

A number of hedge funds and other institutional investors have recently made changes to their positions in INMD. ARGA Investment Management LP increased its stake in InMode by 355.0% during the third quarter. ARGA Investment Management LP now owns 143,658 shares of the healthcare company’s stock valued at $2,141,000 after purchasing an additional 112,087 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new stake in InMode during the third quarter valued at $1,564,000. State of New Jersey Common Pension Fund D increased its stake in InMode by 612.1% during the third quarter. State of New Jersey Common Pension Fund D now owns 96,120 shares of the healthcare company’s stock valued at $1,432,000 after purchasing an additional 82,621 shares during the last quarter. Squarepoint Ops LLC increased its stake in InMode by 92.9% during the second quarter. Squarepoint Ops LLC now owns 143,758 shares of the healthcare company’s stock valued at $2,076,000 after purchasing an additional 69,239 shares during the last quarter. Finally, Doma Perpetual Capital Management LLC increased its stake in InMode by 26.8% during the third quarter. Doma Perpetual Capital Management LLC now owns 2,838,431 shares of the healthcare company’s stock valued at $42,293,000 after purchasing an additional 599,108 shares during the last quarter. Institutional investors own 68.04% of the company’s stock.

InMode Price Performance

INMD opened at $14.65 on Monday. The firm has a market capitalization of $928.22 million, a P/E ratio of 10.17 and a beta of 2.12. The firm’s 50 day moving average is $13.88 and its 200-day moving average is $14.43. InMode has a 52-week low of $12.72 and a 52-week high of $16.74.

InMode (NASDAQ:INMD) last issued its quarterly earnings results on Tuesday, February 10th. The healthcare company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The business had revenue of $103.85 million during the quarter, compared to analyst estimates of $104.64 million. InMode had a net margin of 25.33% and a return on equity of 14.52%. The business’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.42 earnings per share. Equities analysts expect that InMode will post 1.75 earnings per share for the current fiscal year.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.